Strong sales of a new drug helped push Actelion’s earnings higher in the third quarter, prompting Europe’s biggest biotech to upgrade its full-year guidance.
from WSJ.com: US Business http://ift.tt/1ydNOeN
via IFTTT
from WSJ.com: US Business http://ift.tt/1ydNOeN
via IFTTT
No comments:
Post a Comment